(Q33396637)

26 July 2017

Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation (English)

1 reference

26 July 2017

K Hadaya

1

1 reference

26 July 2017

S Ferrari-Lacraz

2

1 reference

26 July 2017

D Fumeaux

3

1 reference

26 July 2017

F Boehlen

4

1 reference

26 July 2017

C Toso

5

1 reference

26 July 2017

S Moll

6

1 reference

26 July 2017

P-Y Martin

7

1 reference

26 July 2017

J Villard

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

10 August 2011

1 reference

American Journal of Transplantation

26 July 2017

1 reference

26 July 2017

11

1 reference

26 July 2017

11

1 reference

26 July 2017

2523-2527

1 reference

Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Eculizumab for paroxysmal nocturnal haemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Eculizumab and renal transplantation in a patient with CAPS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

New insights into postrenal transplant hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Desensitization protocols and their outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Use of rituximab in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03696.X

10.1111/J.1600-6143.2011.03696.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference